GSK
NEWS
Microsoft announced that Emma Walmsley, chief executive officer of GlaxoSmithKline, had been nominated to the company’s board of directors.
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the United States, the company said.
A therapy that leads to fewer asthma attacks while reducing the need for corticosteroids is ideal, especially for those who continue to have severe symptoms while using traditional therapies. That’s where biologics come in.
Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.
With more than 25 years experience in chemotherapeutic products and cancer vaccines, she will lead the ongoing phase I/II trial in NSCLC
Former Principal at Wellington Partners Life Sciences appointed to drive Fund’s European investments
After Joichi “Joi” Ito resigned from his post as director of the MIT Media Lab following revelations of his connections with disgraced financier Jeffrey Epstein, Boston-based Puretech Health announced this morning that he has also resigned from his position as chairman of that company’s board of directors.
Crescendo Biologics Ltd announces that Stewart Kay has been appointed as the Company’s Chief Business Officer.
JOBS
IN THE PRESS